Abstract
Carbonic anhydrase IX (hCA IX) is a membrane-associated glycoprotein that is observed in many tumor tissues and is strongly overexpressed by hypoxia conditions. Hypoxia is a clinically important tumor parameter and this enzyme can play an important role as a potential marker of hypoxic tumor and as a therapeutic target too. In the last years, Carbonic Anhydrase IX Inhibitors which possess fluorescent probe were largely used for visualize hypoxic tumor cell lines and for understanding the biological roles of hCA IX in acidification of the external matrix. Here we resume the developement pathways of such compounds from the design to the final biological evaluation. Furthermore, spin-labeled CAIs were included to have a complete overview of the potenciality of this enzyme as marker of hypoxic tumors.
Keywords: Carbonic anhydrase inhibitors, hCA IX, hypoxic tumor, extracellular pH, fluorescent sulfonamide, spin-labeled sulfonamide
Current Pharmaceutical Design
Title: Fluorescence- and Spin-Labeled Carbonic Anhydrase Inhibitors
Volume: 14 Issue: 7
Author(s): Alessandro Cecchi and Claudiu T. Supuran
Affiliation:
Keywords: Carbonic anhydrase inhibitors, hCA IX, hypoxic tumor, extracellular pH, fluorescent sulfonamide, spin-labeled sulfonamide
Abstract: Carbonic anhydrase IX (hCA IX) is a membrane-associated glycoprotein that is observed in many tumor tissues and is strongly overexpressed by hypoxia conditions. Hypoxia is a clinically important tumor parameter and this enzyme can play an important role as a potential marker of hypoxic tumor and as a therapeutic target too. In the last years, Carbonic Anhydrase IX Inhibitors which possess fluorescent probe were largely used for visualize hypoxic tumor cell lines and for understanding the biological roles of hCA IX in acidification of the external matrix. Here we resume the developement pathways of such compounds from the design to the final biological evaluation. Furthermore, spin-labeled CAIs were included to have a complete overview of the potenciality of this enzyme as marker of hypoxic tumors.
Export Options
About this article
Cite this article as:
Cecchi Alessandro and Supuran T. Claudiu, Fluorescence- and Spin-Labeled Carbonic Anhydrase Inhibitors, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877839
DOI https://dx.doi.org/10.2174/138161208783877839 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antineoplastic Activities, Apoptotic Mechanism of Action and Structural Properties of a Novel Silver(I) Chelate
Current Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Hypothetical Role of Growth Factors to Reduce Intervertebral Disc Degeneration Significantly through Trained Biological Transformations
Current Pharmaceutical Design Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Efficacy and Toxicological Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Updates on the Role of FDG-PET/CT in Gynecological Malignancies
Current Molecular Imaging (Discontinued) Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Development of Medical Images in Differentiating Benign from Malignant Thyroid Nodules
Current Medical Imaging HPV Vaccination in Adolescents: From Clinical Data to Implementation and Practice
Current Cancer Therapy Reviews Organ Preference of Cancer Metastasis and Metastasis-Related Cell Adhesion Molecules Including Carbohydrates
Cardiovascular & Hematological Disorders-Drug Targets Anti-cancer Potential of Phyto-alkaloids: A Prospective Review
Current Cancer Therapy Reviews Nifedipine Blocks Ondansetron Electrophysiological Effects in Rabbit Purkinje Fibers and Decreases Early Afterdepolarization Incidence
Current Clinical Pharmacology PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)